Goto Aya, Wirtz Veronika J, Hayashi Masako, Hasegawa Junichi, Fukushima Kotaro, Matsuda Hideo, Nakai Akihito
Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Center for Integrated Sciences and Humanities, Fukushima Medical University, Fukushima City, Fukushima, Japan.
Prev Med Rep. 2025 Mar 29;53:103041. doi: 10.1016/j.pmedr.2025.103041. eCollection 2025 May.
On April 26, 2023, the Japanese Ministry of Health, Labour and Welfare approved the use of the medical abortion pill package (called the MEFEEGO Pack in Japan) on the condition that the patient undergoes either "hospitalization or outpatient observation at a facility with beds." The purpose of this study is to examine the immediate uptake of medical abortion and the current situation of peri-abortion care in Japan. The study design was an institution-level national survey. Questionnaires were sent to 3941 facilities to collect information on abortions and abortion consultations performed between May and October 2023. Responses were received from 2096 facilities (53.2 % response rate). A total of 28,346 abortions were performed before the ninth week of pregnancy, of which the MEFEEGO Pack was used in 435 cases (1.5 %), with no serious complications. The proportion of facilities providing peri-abortion care services in all abortion cases was 10.9 % for mental health support, 3.3 % for counseling information, 50.6 % for support to prevent repeat abortions, and 73 % for contraceptive information. These services were more commonly provided in hospitals with a higher number of obstetrician-gynecologists and abortions, and where interprofessional collaboration was present. Physicians were the main providers of peri-abortion care, while midwives and nurses provided these services at only about 20 % of facilities. Greater interprofessional collaboration and increased involvement of midwives and nurses are necessary to prepare for a possible increase in the use of medical abortion in Japan.
2023年4月26日,日本厚生劳动省批准使用药物流产药包(在日本称为MEFEEGO Pack),条件是患者要在“有床位的机构住院或门诊观察”。本研究的目的是调查日本药物流产的即时采用情况以及流产前后护理的现状。研究设计为机构层面的全国性调查。向3941家机构发送了问卷,以收集2023年5月至10月期间进行的流产及流产咨询信息。共收到2096家机构的回复(回复率为53.2%)。在妊娠9周前共进行了28346例流产,其中435例(1.5%)使用了MEFEEGO Pack,未出现严重并发症。在所有流产病例中,提供流产前后护理服务的机构比例为:心理健康支持占10.9%,咨询信息占3.3%,预防重复流产支持占50.6%,避孕信息占73%。这些服务在妇产科医生和流产数量较多且存在跨专业协作的医院中更常提供。医生是流产前后护理的主要提供者,而助产士和护士仅在约20%的机构中提供这些服务。为应对日本药物流产使用可能增加的情况,需要加强跨专业协作,并增加助产士和护士的参与度。